Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression

PURPOSE: To explore the activity of dasatinib in combination with docetaxel, gemcitabine, topotecan and doxorubicin in ovarian cancer cells. EXPERIMENTAL DESIGN: Cells with previously determined SRC pathway and protein expression (SRC pathway/SRC protein: IGROV1, both high; SKOV3, both low) were tre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Teoh, Deanna, Jia, Jingquan, Nixon, Andrew B., Grace, Lisa, Adams, David J., Murphy, Susan K., Secord, Angeles Alvarez
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3946897/
https://ncbi.nlm.nih.gov/pubmed/24407585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000056
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak